Perampanel Suspension
Product Images NDC 51672-4256

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Perampanel (NDC 51672-4256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure A (Figure A)

Figure A (Figure A)
This text mentions syringes, bottles, adapters, dosage indicators, and plungers. It seems to describe components of a medical or pharmaceutical device, likely a syringe used for measuring and administering doses of liquid medication.*
FDA Label Image

Figure E (Figure E)

Figure E (Figure E)
FDA Label Image

Figure F (Figure F)

Figure F (Figure F)
FDA Label Image

Figure G (Figure G)

Figure G (Figure G)
FDA Label Image

Figure H (Figure H)

Figure H (Figure H)
FDA Label Image

Figure I (Figure I)

Figure I (Figure I)
FDA Label Image

Figure J (Figure J)

Figure J (Figure J)
FDA Label Image

Carton Label (Carton Image)

Carton Label (Carton Image)
FDA Label Image

Container Label (Label Image)

Container Label (Label Image)
FDA Label Image

Med-guide (Med Guide1)

Med-guide (Med Guide1)
The text provided is a medication guide for Perampanel oral suspension. Perampanel is used to treat partial-onset seizures with or without secondary generalized seizures in individuals with epilepsy who are 4 years of age and older. It can also be used in combination with other medications to treat primary generalized tonic-clonic seizures in individuals who are 12 years of age and older. The guide emphasizes important information regarding mental health risks associated with the medication, such as aggressive behavior, hallucinations, and suicidal thoughts. It warns against sudden discontinuation of the medication and highlights the need for close monitoring of mood and behavior changes. Additionally, it mentions the controlled substance classification of Perampanel due to its potential for abuse. This information aims to educate patients on the risks and benefits of using Perampanel and provides guidance on how to recognize and address potential side effects related to mental health.*
FDA Label Image

Med-guide (Med Guide2)

Med-guide (Med Guide2)
Perampanel oral suspension is a medication used to treat certain types of seizures. It is important to consult with your healthcare provider before taking this medication, especially if you are pregnant, breastfeeding, or taking any other medications. The dosage and administration instructions should be followed carefully as directed by your healthcare provider. Potential side effects of perampanel oral suspension include dizziness, vertigo, problems with walking, sleepiness, tiredness, and an increased risk of falling. It is advised not to drive or operate heavy machinery while taking this medication until you know how it affects you. Additionally, avoiding alcohol or other medications that cause drowsiness is recommended. If a dose is missed, speak with your healthcare provider. If an overdose occurs, contact your local Poison Control Center or go to the nearest hospital emergency room immediately.*
FDA Label Image

Med-guide (Med Guide3)

Med-guide (Med Guide3)
This text provides valuable information about perampanel oral suspension, including potential allergic reactions, common side effects, storage instructions, and general information about its safe and effective use. It also lists the active and inactive ingredients in perampanel oral suspension, as well as details about the manufacturer and distributor. The text emphasizes the importance of following storage guidelines, reporting side effects, and not using the medication for conditions other than those prescribed.*
FDA Label Image

Chemical Structure (Perampanel 01)

Chemical Structure (Perampanel 01)
FDA Label Image

Figure 1 (Perampanel 02)

Figure 1 (Perampanel 02)
This text provides data from three different studies comparing the effectiveness of Perampanel versus Placebo in reducing seizures. Study 1, Study 2, and Study 3 show the percentage of patients experiencing seizures under each treatment, along with the number of patients in each group. The results indicate that Perampanel had a statistically significant effect in reducing seizures compared to Placebo across these studies when accounting for factors such as country and baseline seizure frequency. The analysis was conducted using ANCOVA with treatment and pooled per 28 days as a covariate.*
FDA Label Image

Figure 2 (Perampanel 03)

Figure 2 (Perampanel 03)
FDA Label Image

Figure 3 (Perampanel 04)

Figure 3 (Perampanel 04)
This text provides data on the proportion of patients in different treatment groups. It shows the percentage of patients falling within specific ranges of improvement or worsening. The data appears to compare a treatment group (Perampanel) with a placebo group, with N=81 for the Perampanel group.*
FDA Label Image

Figure B (Perampanel 06)

Figure B (Perampanel 06)
FDA Label Image

Figure C (Perampanel 07)

Figure C (Perampanel 07)
FDA Label Image

Figure D (Perampanel 08)

Figure D (Perampanel 08)
FDA Label Image

Figure K (Perampanel 15)

Figure K (Perampanel 15)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.